Efficacy and Safety of Intravenous and Subcutaneous Secukinumab in Moderate to Severe Chronic Plaque-type Psoriasis
Status:
Completed
Trial end date:
2013-04-01
Target enrollment:
Participant gender:
Summary
The study will assess the safety and efficacy of intravenous (10mg/kg) and subcutaneous
(300mg) secukinumab in moderate to severe chronic plaque-type psoriasis who are partial
responders to secukinumab.